LENSAR (LNSR) Competitors $5.80 +0.17 (+3.02%) Closing price 04:00 PM EasternExtended Trading$5.60 -0.20 (-3.43%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LNSR vs. TLSI, SI, PROF, CARL, and RXSTShould you buy LENSAR stock or one of its competitors? MarketBeat compares LENSAR with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENSAR include TriSalus Life Sciences (TLSI), Shoulder Innovations (SI), Profound Medical (PROF), Carlsmed (CARL), and RxSight (RXST). These companies are all part of the "medical equipment" industry. LNSR vs. TLSILNSR vs. SILNSR vs. PROFLNSR vs. CARLLNSR vs. RXSTHow does LENSAR compare to TriSalus Life Sciences?LENSAR (NASDAQ:LNSR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Is LNSR or TLSI more profitable? LENSAR has a net margin of 50.94% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR50.94% -183.19% 42.26% TriSalus Life Sciences -60.85%N/A -69.91% Does the media refer more to LNSR or TLSI? In the previous week, TriSalus Life Sciences had 11 more articles in the media than LENSAR. MarketBeat recorded 12 mentions for TriSalus Life Sciences and 1 mentions for LENSAR. TriSalus Life Sciences' average media sentiment score of 0.66 beat LENSAR's score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Do insiders and institutionals believe in LNSR or TLSI? 40.2% of LENSAR shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 66.0% of LENSAR shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, LNSR or TLSI? LENSAR has higher revenue and earnings than TriSalus Life Sciences. LENSAR is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$58.44M1.20-$34.28M-$0.58N/ATriSalus Life Sciences$45.15M4.28-$39.23M-$1.41N/A Do analysts rate LNSR or TLSI? LENSAR currently has a consensus target price of $10.00, indicating a potential upside of 72.41%. TriSalus Life Sciences has a consensus target price of $7.50, indicating a potential upside of 138.10%. Given TriSalus Life Sciences' higher probable upside, analysts plainly believe TriSalus Life Sciences is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Which has more volatility and risk, LNSR or TLSI? LENSAR has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. SummaryLENSAR beats TriSalus Life Sciences on 9 of the 15 factors compared between the two stocks.How does LENSAR compare to Shoulder Innovations?LENSAR (NASDAQ:LNSR) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability. Is LNSR or SI more profitable? LENSAR has a net margin of 50.94% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR50.94% -183.19% 42.26% Shoulder Innovations -81.78%-35.11%-20.58% Does the media prefer LNSR or SI? In the previous week, Shoulder Innovations had 8 more articles in the media than LENSAR. MarketBeat recorded 9 mentions for Shoulder Innovations and 1 mentions for LENSAR. Shoulder Innovations' average media sentiment score of 0.41 beat LENSAR's score of 0.00 indicating that Shoulder Innovations is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shoulder Innovations 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LNSR or SI? LENSAR currently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Shoulder Innovations has a consensus price target of $21.00, indicating a potential upside of 40.53%. Given LENSAR's higher possible upside, research analysts plainly believe LENSAR is more favorable than Shoulder Innovations.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Shoulder Innovations 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Which has higher earnings and valuation, LNSR or SI? LENSAR has higher revenue and earnings than Shoulder Innovations. LENSAR is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$58.44M1.20-$34.28M-$0.58N/AShoulder Innovations$47.32M6.55-$40.36M-$166.96N/A Do institutionals & insiders believe in LNSR or SI? 40.2% of LENSAR shares are owned by institutional investors. 66.0% of LENSAR shares are owned by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryLENSAR beats Shoulder Innovations on 8 of the 15 factors compared between the two stocks.How does LENSAR compare to Profound Medical?LENSAR (NASDAQ:LNSR) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment. Do institutionals and insiders believe in LNSR or PROF? 40.2% of LENSAR shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 66.0% of LENSAR shares are held by insiders. Comparatively, 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation & earnings, LNSR or PROF? LENSAR has higher revenue and earnings than Profound Medical. LENSAR is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$58.44M1.20-$34.28M-$0.58N/AProfound Medical$16.10M15.19-$42.57M-$1.24N/A Do analysts rate LNSR or PROF? LENSAR currently has a consensus target price of $10.00, indicating a potential upside of 72.41%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 78.31%. Given Profound Medical's higher possible upside, analysts plainly believe Profound Medical is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Profound Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is LNSR or PROF more profitable? LENSAR has a net margin of 50.94% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR50.94% -183.19% 42.26% Profound Medical -206.76%-78.88%-64.06% Which has more risk and volatility, LNSR or PROF? LENSAR has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Does the media refer more to LNSR or PROF? In the previous week, Profound Medical had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for Profound Medical and 1 mentions for LENSAR. Profound Medical's average media sentiment score of 0.60 beat LENSAR's score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Profound Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLENSAR beats Profound Medical on 9 of the 16 factors compared between the two stocks.How does LENSAR compare to Carlsmed?LENSAR (NASDAQ:LNSR) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Do analysts rate LNSR or CARL? LENSAR currently has a consensus price target of $10.00, indicating a potential upside of 72.41%. Carlsmed has a consensus price target of $19.33, indicating a potential upside of 71.24%. Given LENSAR's higher probable upside, research analysts clearly believe LENSAR is more favorable than Carlsmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Carlsmed 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has stronger earnings and valuation, LNSR or CARL? Carlsmed has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$58.44M1.20-$34.28M-$0.58N/ACarlsmed$50.51M6.08-$29.63M-$2.51N/A Is LNSR or CARL more profitable? LENSAR has a net margin of 50.94% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR50.94% -183.19% 42.26% Carlsmed -57.76%-60.74%-29.84% Does the media refer more to LNSR or CARL? In the previous week, LENSAR had 1 more articles in the media than Carlsmed. MarketBeat recorded 1 mentions for LENSAR and 0 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.89 beat LENSAR's score of 0.00 indicating that Carlsmed is being referred to more favorably in the news media. Company Overall Sentiment LENSAR Neutral Carlsmed Very Positive Do institutionals & insiders believe in LNSR or CARL? 40.2% of LENSAR shares are held by institutional investors. 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryLENSAR beats Carlsmed on 8 of the 15 factors compared between the two stocks.How does LENSAR compare to RxSight?LENSAR (NASDAQ:LNSR) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Do institutionals and insiders hold more shares of LNSR or RXST? 40.2% of LENSAR shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 66.0% of LENSAR shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is LNSR or RXST more profitable? LENSAR has a net margin of 50.94% compared to RxSight's net margin of -36.58%. RxSight's return on equity of -17.01% beat LENSAR's return on equity.Company Net Margins Return on Equity Return on Assets LENSAR50.94% -183.19% 42.26% RxSight -36.58%-17.01%-15.12% Which has more volatility & risk, LNSR or RXST? LENSAR has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, RxSight has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Does the media prefer LNSR or RXST? In the previous week, RxSight had 1 more articles in the media than LENSAR. MarketBeat recorded 2 mentions for RxSight and 1 mentions for LENSAR. LENSAR's average media sentiment score of 0.00 equaled RxSight'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend LNSR or RXST? LENSAR currently has a consensus target price of $10.00, suggesting a potential upside of 72.41%. RxSight has a consensus target price of $9.44, suggesting a potential upside of 58.73%. Given LENSAR's stronger consensus rating and higher probable upside, analysts clearly believe LENSAR is more favorable than RxSight.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33RxSight 3 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.93 Which has better earnings and valuation, LNSR or RXST? LENSAR has higher earnings, but lower revenue than RxSight. LENSAR is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENSAR$58.44M1.20-$34.28M-$0.58N/ARxSight$134.48M1.83-$38.94M-$1.13N/A SummaryLENSAR and RxSight tied by winning 7 of the 14 factors compared between the two stocks. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition ExportMetricLENSARMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.15M$6.99B$6.25B$12.23BDividend YieldN/A1.69%2.80%5.27%P/E Ratio-10.0040.2517.5422.48Price / Sales1.2070.19531.2172.17Price / CashN/A24.4943.0954.25Price / Book6.526.249.816.83Net Income-$34.28M$158.81M$3.55B$335.69M7 Day Performance-1.36%-1.12%-2.07%-2.03%1 Month Performance-2.19%-5.54%-3.90%-1.90%1 Year Performance-58.87%-4.51%29.39%27.36% LENSAR Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR1.5357 of 5 stars$5.80+3.0%$10.00+72.4%-60.1%$68.15M$58.44MN/A110Analyst DowngradeTLSITriSalus Life Sciences3.5053 of 5 stars$4.56+0.4%$7.00+53.5%-41.1%$278.33M$45.15MN/A106News CoverageInsider TradeGap UpSIShoulder Innovations4.0569 of 5 stars$13.36+1.0%$21.00+57.2%N/A$274.02M$47.32MN/A61Earnings ReportPROFProfound Medical1.5504 of 5 stars$7.14-1.5%$12.00+68.1%+46.3%$263.45M$16.10MN/A150CARLCarlsmed3.2888 of 5 stars$9.83+1.8%$19.33+96.7%N/A$262.61M$56.44MN/A100Positive News Related Companies and Tools Related Companies TriSalus Life Sciences Competitors Shoulder Innovations Competitors Profound Medical Competitors Carlsmed Competitors RxSight Competitors Orchestra BioMed Competitors Electromed Competitors Embecta Competitors Lucid Diagnostics Competitors KORU Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LNSR) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
